Nexavar clinical data presented at ASCO

Lung cancer – Phase II results show ‘encouraging’ results in heavily pre-treated patients. Nexavar continuation resulted in longer periods of disease control
Thyroid Cancer -Phase II results show Nexavar displayed anti-tumor activity in the majority of patients
GIST - Phase II results show that Nexavar is active and well tolerated in patients with Gleevec or Gleevec and Sutent resistant GIST.
Gastric Cancer – Phase II results show ‘encouraging’ data when administered with docetaxel and cisplatin
Ovarian Cancer – Phase II results show Nexavar is active and tolerated in patients with recurrent epithelial ovarian cancer